The global gastroesophageal reflux disease therapeutics market size was valued at USD 4.36 billion in 2020 and is estimated to expand at a moderate CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the wide prevalence of GERD due to change in the lifestyle of the people and increasing awareness regarding the disease.
Gastroesophageal reflux disease is a digestive disease that irritates the lining of food pipe due to stomach acid also known as bile. This is a chronic disorder that irritates the food pipe lining when stomach acid flows into the food pipelining. GERD is indicated when heartburn and acid reflux occurs more than twice a week. The most common symptom of GERD is burning chest pain that occurs after eating and this condition worsens when the individual lies down. The temporary solutions for the disease are over-the-counter medications and changes in lifestyle; however, specific cases may require medications that are stronger.
As per the reports published by the World Health Organization (WHO) in 2017, nearly USD 10 billion were spent on antacids every year. A report by the World Gastroenterology Organization also suggests that the global cases of GERD are increasing rapidly. Acid complications are quite frequent in the elderly population that proves to be quite challenging for gastroenterologists and primary care providers. Moreover, the market is expected to grow due to the increasing number of companies for the treatment of acid reflux disorders.
The report on the global gastroesophageal reflux disease therapeutics market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Gastroesophageal Reflux Disease Therapeutics Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Drug Types (Antacids, Proton Pump Inhibitors, H2 Receptor Blockers, and Pro-Kinetic Agents) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
RaQualia Pharma, Inc.; AstraZeneca PLC; GlaxoSmithKline PLC; Daewoong Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Johnson & Johnson; Eisai Co., Ltd.; SRS Pharmaceuticals Pvt. Ltd.; Ironwood Pharmaceuticals, Inc.; and SFJ Pharmaceuticals |
On the basis of drug types, the global gastroesophageal reflux disease therapeutics market is divided into antacids, proton pump inhibitors, H2 receptor blockers, and pro-kinetic agents. The antacids segment held a major share of the market in 2019 and is expected to dominate the market in the coming years. The segment growth is attributed to easily available of the drugs in various forms including syrups, powders, and tablets, and provides immediate relief from infrequent and mild symptoms by neutralizing gastric acid secretions.
Meanwhile, the proton pump inhibitors segment is projected to account for a key market share during the targeted period owing to the wide recommendation of the medication and is commonly prescribed by professionals for heartburn treatment.
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a high share of the market in 2019 and is anticipated to account for a large market share during the projected period owing to increasing number of people experiencing symptoms of the GERD and increasing number of clinical visits by the geriatric population due to acid reflux and heartburn. However, the market in Asia Pacific is anticipated to grow at a rapid pace due to rising cases of obesity, change in lifestyle, and increasing geriatric population in the region.
The global gastroesophageal reflux disease therapeutics market has been segmented on the basis of
Key players competing in the global gastroesophageal reflux disease therapeutics market are RaQualia Pharma, Inc.; AstraZeneca PLC; GlaxoSmithKline PLC; Daewoong Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Johnson & Johnson; Eisai Co., Ltd.; SRS Pharmaceuticals Pvt. Ltd.; Ironwood Pharmaceuticals, Inc.; and SFJ Pharmaceuticals.
Many of these players have adopted business strategies such as the launch of new products, the advancement of technology, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally. For instance, RaQualia Pharma, Inc. and Ironwood Pharmaceuticals, Inc. are extensively focused on developing new generic molecules to expand their business operations.
Some other reports from this category!